Arch Biopartners Stock Price, News & Analysis

Arch Biopartners Inc. (OTCQB: ACHFF) announced a successful increase in the maximum daily dose of its lead drug candidate, LSALT peptide, to 20 mg in a human trial in Australia. This trial confirmed the safety and tolerability of the new dosage, paving the way for a Phase II trial aimed at treating cardiac surgery-associated acute kidney injury (CS-AKI). Previously, LSALT peptide was administered at a maximum of 5 mg during a Phase II trial for COVID-19 patients. Arch is also advancing the production of 10,000 vials of LSALT peptide for future non-COVID trials, expected to be ready by May 2023. The trial took place at the Alfred Hospital in Melbourne, involving sixteen healthy volunteers. The new safety data will be included in a future IND application to the U.S. FDA.

Arch Biopartners Inc. (ACHFF) announced a significant partnership with the National Research Council of Canada Industrial Research Assistance Program, receiving up to $4,000,000 to enhance the LSALT peptide (Metablok) program aimed at treating acute inflammation in critical organs. The funding will support essential research tasks including dosing studies, Phase III human trials for COVID-19, and Phase II trials for cardiac surgery-related kidney injury. This initiative is expected to propel the drug development process over the next twelve months, with the project term concluding on March 31, 2024.

Arch Biopartners Inc. announced the receipt of a CIHR Project Grant of $1,109,250 for research into dipeptidase-1 (DPEP-1) and its connections to renal inflammation and chronic kidney disease (CKD). The award was given to a team led by Dr. Daniel Muruve at the University of Calgary, who is also Chief Science Officer at Arch. This funding will support efforts to understand how DPEP-1 influences kidney disease, potentially leading to new therapeutic targets. Arch is focused on innovative treatments for organ inflammation, aiming to improve outcomes for conditions like acute kidney injury.